Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs

Cancer Biology and Therapy

Volumn 9, Issue 7, 2010, Pages 523-525

  Indovina, Paola ^a,b   Giordano, Antonio ^a,b,c  

^a UNIVERSITY OF SIENA   (Italy)

^b Temple University   (United States)

^c CROM Center of Oncology Research Mercogliano   (Italy)

Author keywords

DNA damaging agents; MK 1775; p53 deficient cancer cells; WEE1

Indexed keywords

CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DNA; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; MK 1775; PEMETREXED; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WEE 1 KINASE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL CYCLE G2 PHASE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; NONHUMAN; NOTE; PROTEIN FUNCTION; SENSITIZATION; SOLID TUMOR;

EID: 77953726033     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.7.11276     Document Type: Note

References (23)

1. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25.
2. Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature 1975; 254:245-7.
3. Weinert TA, Hartwell LH. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 1988; 241:317-22.
4. Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 1982; 79:2942-6.
5. 2 checkpoint abrogation. Cancer Res 1999; 59:5887-91.
6. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:523-5.
7. 2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545-54.
8. Perry JA, Kornbluth S. Cdc25 and Wee1: analogous opposites? Cell Div 2007; 2:12.
9. Stracker TH, Theunissen JW, Morales M, Petrini JH. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair (Amst) 2004; 3:845-54.
10. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13:1955-60.
11. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513-9.
12. 2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305-13.
13. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001; 61:8211-7.
14. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992-3000.
15. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, et al. Small interfering RNA screen reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006; 26:9377-86.
16. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
17. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002; 7:11-7.
18. Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007; 28:13-20.
19. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7:2394-404.
20. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66.
21. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the antitumor activity of gemcitabine in vivo. Cell Cycle 2007; 6:104-10.
22. Menoyo A, Alazzouzi H, Espín E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61:7727-30.
23. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002; 62:4095-9.